RAC 2.20% $1.78 race oncology ltd

been looking all over for all comer trials…. There just isn’t a...

  1. 2,849 Posts.
    lightbulb Created with Sketch. 2901
    been looking all over for all comer trials…. There just isn’t a lot to be honest. Think that most biotechs and pharma for that matter are risk averse and simply hope a single indication shows efficacy. What does this say about Race’s confidence to run all comers trial, they are going all in!

    Keytruda was one of a few all comer approvals and generally a subset biomarker or mutation. Rather than different cancer types. Expecting the readout won’t go unnoticed for long.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.